

Amend CSHB 2292 as follows:

Section 2.12. On page 70, line 13, insert new subsections (a-1) and (a-2) to read as follows:

(a-1) The commission shall delay requiring a prior authorization for drugs listed in subsection (b) until the commission has completed a study evaluating the impact of a requirement of prior authorization on the recipients of certain drug classes.

(a-2) Drugs subject to the study in subsection (b) include drugs used in the treatment of:

(1) cancer and cancer-supportive care,

(2) End-stage Renal Disease,

(3) chronic non-malignant pain,

(4) hemophilia, and

(5) multiple sclerosis.